Posted by Michael Wonder on 29 Mar 2023
Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund
29 March 2023 - It is estimated that around 400 people with advanced cervical cancer will be eligible for pembrolizumab (also known as Keytruda and made by Merck Sharp and Dohme) through the CDF.
Clinical trial evidence shows that people on the treatment have longer without their disease getting worse than people having standard care.
